Incendia Therapeutics, Inc. Logo Skip to main content
  • About
  • Team
  • Pipeline
  • News
    • Presentations & Publications
    • Press Releases
    • In the News
  • Careers
    • Overview
    • Job Opportunities
  • Contact

Press Releases

December 11, 2024 | Incendia Therapeutics Appoints Renowned Biotechnology Investor and Entrepreneur Louis G. Lange, M.D., Ph.D., to Board of Directors

December 3, 2024 | Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

September 10, 2024 | Incendia Therapeutics Enrolls First Patient in Phase 1c Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor

May 23, 2024 | Incendia Therapeutics Announces Upcoming Presentation with PathAI at the 2024 American Society of Clinical Oncology Annual Meeting

April 5, 2024 | Incendia Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research 2024

November 22, 2023 | Incendia Therapeutics to Present at 35th Annual Piper Sandler Healthcare Conference

November 13, 2023 | Incendia Therapeutics Appoints Wendye Robbins, M.D., as Chief Executive Officer and Doses First Patient in Phase 1b Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor

October 31, 2023 | Incendia Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 38th Annual Meeting

October 16, 2023 | Incendia Therapeutics Announces Upcoming Presentations at the European Society for Medical Oncology Congress 2023

  • Presentations & Publications
  • Press Releases
  • In the News
  • Home
  • About
  • Team
  • Pipeline
  • News
    • Presentations & Publications
    • Press Releases
    • In the News
  • Careers
    • Overview
    • Job Opportunities
  • Contact
Incendia Therapeutics, Inc. Logo

Incendia Therapeutics, Inc.
One Canal Park
Suite# 200
Cambridge, MA 02141

Contact

Business Development
bd@incendiatx.com

General Inquires
info@incendiatx.com

  • LinkedIn
  • Privacy Statement
  • Terms of Use
© 2025 Incendia Therapeutics, Inc. All rights reserved.
Website Design: Hane Chow, Inc.